Berliner Boersenzeitung - Highly awaited Alzheimer's drug hit by delays

EUR -
AED 3.825884
AFN 70.312965
ALL 98.172348
AMD 405.983344
ANG 1.878684
AOA 950.992104
ARS 1046.039232
AUD 1.602332
AWG 1.877506
AZN 1.774876
BAM 1.957138
BBD 2.104639
BDT 124.563946
BGN 1.956544
BHD 0.39257
BIF 3015.466631
BMD 1.041612
BND 1.404994
BOB 7.203027
BRL 6.04
BSD 1.042413
BTN 87.986953
BWP 14.240939
BYN 3.411414
BYR 20415.594464
BZD 2.101187
CAD 1.456049
CDF 2990.468321
CHF 0.931639
CLF 0.037246
CLP 1027.738103
CNY 7.545129
CNH 7.56203
COP 4603.508229
CRC 530.962924
CUC 1.041612
CUP 27.602717
CVE 110.727408
CZK 25.347006
DJF 185.115688
DKK 7.459145
DOP 62.965852
DZD 139.882279
EGP 51.734825
ERN 15.624179
ETB 128.129096
FJD 2.371178
FKP 0.822162
GBP 0.831134
GEL 2.854424
GGP 0.822162
GHS 16.461485
GIP 0.822162
GMD 73.95482
GNF 8990.153218
GTQ 8.0465
GYD 218.082204
HKD 8.108481
HNL 26.280274
HRK 7.430088
HTG 136.833528
HUF 411.72878
IDR 16596.315881
ILS 3.856089
IMP 0.822162
INR 87.95601
IQD 1365.032477
IRR 43844.055504
ISK 145.517163
JEP 0.822162
JMD 166.063508
JOD 0.738611
JPY 161.25928
KES 134.892709
KGS 90.103392
KHR 4219.570425
KMF 492.165604
KPW 937.450371
KRW 1462.980499
KWD 0.320661
KYD 0.868706
KZT 520.483256
LAK 22873.799058
LBP 93328.432197
LKR 303.387371
LRD 187.490516
LSL 18.884822
LTL 3.07561
LVL 0.630061
LYD 5.088315
MAD 10.430651
MDL 19.01327
MGA 4864.328226
MKD 61.529504
MMK 3383.115023
MNT 3539.397392
MOP 8.357733
MRU 41.565566
MUR 48.799915
MVR 16.103715
MWK 1807.197114
MXN 21.322322
MYR 4.653963
MZN 66.569813
NAD 18.884818
NGN 1767.306896
NIO 38.279632
NOK 11.534634
NPR 140.779605
NZD 1.786042
OMR 0.401061
PAB 1.042438
PEN 3.951916
PGK 4.19327
PHP 61.415565
PKR 289.363658
PLN 4.33652
PYG 8137.562185
QAR 3.791992
RON 4.977139
RSD 117.017853
RUB 108.691187
RWF 1427.008389
SAR 3.910739
SBD 8.732411
SCR 14.876528
SDG 626.533424
SEK 11.498605
SGD 1.404201
SHP 0.822162
SLE 23.676226
SLL 21842.08698
SOS 595.285051
SRD 36.971015
STD 21559.264616
SVC 9.121147
SYP 2617.081156
SZL 18.88481
THB 35.925581
TJS 11.101548
TMT 3.645642
TND 3.312851
TOP 2.439563
TRY 35.99228
TTD 7.079839
TWD 33.914681
TZS 2770.688169
UAH 43.124062
UGX 3851.632667
USD 1.041612
UYU 44.329875
UZS 13363.881826
VES 48.495212
VND 26476.734473
VUV 123.662265
WST 2.907755
XAF 656.421432
XAG 0.033316
XAU 0.000385
XCD 2.815009
XDR 0.792961
XOF 650.490415
XPF 119.331742
YER 260.324909
ZAR 18.881446
ZMK 9375.761332
ZMW 28.796097
ZWL 335.398627
  • RBGPF

    -0.5000

    59.69

    -0.84%

  • SCS

    0.2300

    13.27

    +1.73%

  • NGG

    1.0296

    63.11

    +1.63%

  • AZN

    1.3700

    65.63

    +2.09%

  • GSK

    0.2600

    33.96

    +0.77%

  • RIO

    -0.2200

    62.35

    -0.35%

  • BTI

    0.4000

    37.38

    +1.07%

  • BP

    0.2000

    29.72

    +0.67%

  • CMSC

    0.0320

    24.672

    +0.13%

  • CMSD

    0.0150

    24.46

    +0.06%

  • RELX

    0.9900

    46.75

    +2.12%

  • BCC

    3.4200

    143.78

    +2.38%

  • BCE

    0.0900

    26.77

    +0.34%

  • VOD

    0.1323

    8.73

    +1.52%

  • RYCEF

    0.0100

    6.8

    +0.15%

  • JRI

    -0.0200

    13.21

    -0.15%

Highly awaited Alzheimer's drug hit by delays
Highly awaited Alzheimer's drug hit by delays / Photo: PHILIPPE LOPEZ - AFP

Highly awaited Alzheimer's drug hit by delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

Text size:

Donanemab has been found to slow cognitive decline in the early stages of the disease during a clinical trial -- but there was also a high rate of side effects, including deaths.

The Food and Drug Administration (FDA) "has informed Lilly it wants to further understand topics related to evaluating the safety and efficacy of donanemab," the company said in a statement Friday.

The regulator told the Indiana-based company it would convene a new meeting of experts, but hadn't provided a firm date. "As a result, the timing of expected FDA action on donanemab will be delayed beyond the first quarter of 2024."

"We are confident in donanemab's potential to offer very meaningful benefits to people with early symptomatic Alzheimer's disease," said Anne White, the company's executive vice president.

She added the FDA's decision to have a new meeting was "unexpected," but "We will work with the FDA and the stakeholders in the community to make that presentation and answer all questions."

Donanemab is an intravenously injected antibody that targets the build up beta-amyloid, a protein found in the brains of many patients with Alzheimer's.

Another anti-amyloid therapy called Leqembi, which was developed by Eisai of Japan and Biogen of Massachusetts, was granted full approval by the FDA last July and is now accessible through government-run health insurance for the elderly called Medicare.

- Slows decline, but risky -

In a paper published in the Journal of the American Medical Association last year, researchers found donanemab slowed cognitive and functional decline in patients who have early symptoms of the disease.

Forty-seven percent of those who received the drug showed no signs of cognitive decline after one year of treatment, compared to 29 percent who received a placebo.

Serious adverse events, including brain bleeds, occurred in 17.4 percent of those who received donanemab and 15.8 percent of those who received a placebo.

There were also four deaths: three in the donanemab group and one in the placebo group, but all the fatalities were considered a result of the treatment they received.

The trial recruited participants aged 60 to 85 with early symptomatic Alzheimer's, either mild cognitive impairment or Alzheimer's disease with mild dementia.

The news comes after the first Alzheimer's drug to be approved was pulled from the market in January.

The FDA awarded accelerated approval to Aduhelm in June 2021, a decision that was contentious at the time because the agency overruled its own independent advisors, who found there was insufficient evidence of benefit.

Biogen, which co-developed Aduhelm with Eisai, said it was discontinuing Aduhelm to focus its efforts of Leqembi.

Alzheimer's is the most common form of dementia. More than one in nine people over 65 develop the condition, which worsens over time, robbing them of their memories and independence, according to the US Alzheimer's Association.

(Y.Yildiz--BBZ)